Eculizumab Is Safe and Effective as a Long-term Treatment for Protein-losing Enteropathy Due to CD55 Deficiency

MLA

Kurolap, Alina, et al. “Eculizumab Is Safe and Effective as a Long-Term Treatment for Protein-Losing Enteropathy Due to CD55 Deficiency.” Journal of Pediatric Gastroenterology & Nutrition, vol. 68, no. 3, Mar. 2019, pp. 325–33. EBSCOhost, https://doi.org/10.1097/MPG.0000000000002198.

APA

Kurolap, A., Eshach Adiv, O., Hershkovitz, T., Tabib, A., Karbian, N., Paperna, T., Mory, A., Vachyan, A., Slijper, N., Steinberg, R., Zohar, Y., Mevorach, D., & Baris Feldman, H. (2019). Eculizumab Is Safe and Effective as a Long-term Treatment for Protein-losing Enteropathy Due to CD55 Deficiency. Journal of Pediatric Gastroenterology & Nutrition, 68(3), 325–333. https://doi.org/10.1097/MPG.0000000000002198

Chicago

Kurolap, Alina, Orly Eshach Adiv, Tova Hershkovitz, Adi Tabib, Netanel Karbian, Tamar Paperna, Adi Mory, et al. 2019. “Eculizumab Is Safe and Effective as a Long-Term Treatment for Protein-Losing Enteropathy Due to CD55 Deficiency.” Journal of Pediatric Gastroenterology & Nutrition 68 (3): 325–33. doi:10.1097/MPG.0000000000002198.